Evidence map›Paper›PMID 33095513›Full record

SynthesisJournal of medical virology2021

The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.

Yixuan Wang, Baixin Chen, Yun Li, Lei Zhang, Yuyi Wang, Shuaibing Yang, Xue Xiao, Qingsong Qin

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 5 pooled it
1.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 5 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19.International journal of medical sciences · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Potential use of renin-angiotensin-aldosterone system inhibitors to reduce COVID-19 severity.Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology · 2023
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yixuan WangLaboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, Guangdong Province, China.
Baixin ChenDepartment of Sleep Medicine, Shantou University Mental Health Center, Shantou University Medical College, Shantou, Guangdong Province, China.
Yun LiDepartment of Sleep Medicine, Shantou University Mental Health Center, Shantou University Medical College, Shantou, Guangdong Province, China.
Lei ZhangHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yuyi WangLaboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, Guangdong Province, China.
Shuaibing YangLaboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, Guangdong Province, China.
Xue XiaoLaboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, Guangdong Province, China.
Qingsong QinLaboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, Guangdong Province, China.ORCID 0000-0001-6315-5809
Shantou University · CNTongji Hospital · CN

Funding

Department of Education of Guangdong province of China 2017KTSCX067Department of Education of Guangdong province of China 2020KZDZX1084National Natural Science Foundation of China 82072292Natural Science Foundation of Guangdong province of China 2018A030307061Science and Technology Bureau of Shantou City, Guangdong, China 200114115876753
6 · The paper itself

Abstract

Renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are one of the most prescribed antihypertensive medications. Previous studies showed RAAS inhibitors increase the expression of ACE2, a cellular receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which provokes a concern that the use of ACEI and ARB in hypertensive individuals might lead to increased mortality and severity of coronavirus disease 2019 (COVID-19). To further investigate the effects of ACEI/ARB on COVID-19 patients, we systematically reviewed relevant studies that met predetermined inclusion criteria in search of PubMed, Embase, Cochrane Library databases, medRxiv, and bioRxiv. The search strategy included clinical data published through October 12, 2020. Twenty-six studies involving 8104 hypertensive patients in ACEI/ARB-treated group and 8203 hypertensive patients in non-ACEI/ARB-treated group were analyzed. Random-effects meta-analysis showed ACEI/ARB treatment was significantly associated with a lower risk of mortality in hypertensive COVID-19 patients (odds ratio [OR] = 0.624, 95% confidence interval [CI] = 0.457-0.852, p = .003, I

Indexed as

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsComorbidityCOVID-19FemaleHumansHypertensionMalePrognosisRisk FactorsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsACEI/ARBCOVID-19hypertensionmortality

Identifiers

PMID33095513
OpenAlexW3094330554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.